Mohamed Kabbout Email & Phone Number

Rockville, Md, Us

- Created and managed multiple complex research plans that resulted in the accomplishment of multiple business objectives. - Assumed direct people management responsibility with high level of autonomy and some decision making. - Drove the advancement of portfolio programs through the drug development pipeline to NME/IND. - Highly motivated and dedicated with excellent scientific track record.- Organized, work well in a team setting, demonstrate leadership and sensitive to timelines. - Experience in solid tumor drug discovery and efficiently collaborate with colleagues in the oncology, chemistry and antibody development groups, and present scientific results to multidisciplinary teams

•Developed oncolytic virus (OV) HSV-1 therapy with immuno-payloads: Performed DNA cloning and sequencing to generate OV, FACS and ELISA based assays to verify payloads expression, followed by plaques assays in Vero and tumor cells. Followed GMP and GLP regulations to bring OV to clinic.Executed and interpreted 2D and 3D in vitro studies for different portfolio, LS (lead selection) and CS (candidate selection) projects (T cells killing assays using different format antigen-CD3 bispecific redirectors/ Cytotoxicity assays for different format ADC).• Developed Flow cytometry methods to measure tumor antigens receptor densities for patients derived DTC (Dissociated Tumors cells), in vivo CDX and PDX as well as in vitro efficacy models.• Engineered cell lines for in vivo and in vitro efficacy studies for different portfolio, LS and CS projects.• Validated new targets (Synthetic lethal, plasma membrane clipped targets) to be advanced from pre-portfolio to portfolio using different methods (Crisper-Cas9, shRNA, ELISA, FACS and western blot analysis, cytotoxicity assays, clonogenic assays).• Developed new methods to measure T cell activation using 8+ colors flow cytometry as well as MSD assays.• Developed bladder organoids models for different tumor antigen apical targets.• Developed immunofluorescence methods to stain bladder organoids (using basal and apical markers).• Mentored less experienced colleagues.• Managed multiple projects in a fast-paced environment.• Presented data to leadership and stack holders about progress of different projects.• Worked closely with protein engineering teams to develop antibodies to support different pre-portfolio and portfolio projects.• Followed DDI guidelines for ELN (Electronic Notebook experiment creation, submission and review). Submitted tech reports IND application submission.• Followed basic safety laboratory guidelines.

Falls Church, Virginia, Us

Appointed as research scientist to synthetize and develop anti-cancer stem cell adenoviral therapy for the treatment of colon cancer.• Engineered conditional replicative adenovirus using different gene assembly techniques.• Used in vitro 3D culture system, in vivo tumor model and flow cytometry to quantify stem cells in colorectal cancer.• Used Flow cytometry, Elisa and other assays to analyze immunogenicity in colorectal cancer.• Determined the oncolytic activity of adenovirus in colon cancer using plaque assays, focus forming assays, endpoint dilution assays, Flow cytometry, Elisa and qPCR.• Collaborated with colleagues at Inova to study adenoviral transmission in simulated microgravity for the National Aeronautics and Space Administration (NASA).• Started a new project with the laboratory of Dr. Sanjay Vashee at the J.Craig Venter Institute to develop an anti-cancer stem cell HSV-1 therapy for the treatment of colorectal cancer using Transformation Associated Recombination in yeast.

Fairfax, Virginia , Us

Bethesda, Maryland, Us

Appointed as biologist to lead projects aimed at understanding disparities in breast cancer through the identification of epigenetic and metabolic diagnostic and prognostic markers as well as novel epigenetic drug inhibitors.• Determined the specific epigenetic functions of CtBP1 and CtBP2 after engineering of lentiviral vectors for overexpression and knock down of CtBP1 and CtBP2 in breast cancer progression cell lines model.• Conducted mechanistic molecular studies using breast cancer patient specimens and cell lines.• Characterized the molecular and cellular functions of a novel metabolic anti-cancer drug that targets CtBP2 oncogenic marker in preclinical models.• Identified CtBP2 as a potential marker for breast cancer diagnosis and prognosis.• Identified and characterized drug resistance pathways in breast cancer patients’ tissues and cell lines in response to metabolic imbalance. • Determined methylation, epigenetic and genetic patterns in breast cancer disparities.• Established different collaborations at NIH and reported research outcomes and recommendations for future work to principal investigator.• Participated in the training of staff as appropriate.

St. Louis, Mo, Us

Appointed as Project Lead for: 1) Finding biomarkers that can be targeted by combination therapy in Avastin treatment-resistant Glioblastomas (GBM), and 2) Identifying diagnostic biomarkers in cancer stem cells at tumor initiation and dormancy stages in breast cancer preclinical models. • Induced GBM in mouse models after engineering of lentiviral vectors expressing the PDGFB oncogene.• Supervised technicians in applying experimental protocols, and presented data to stakeholders.• Developed preclinical GBM mouse model, and analyzed the expression of potential GBM prognostic markers in TCGA and institutional datasets. • Established methods to analyze cancer stem cells from bone marrow/breast tissues of transgenic mice.

Houston, Tx, Us

Successfully characterized ETS2 gene as: 1) Poor prognostic biomarker, and 2) Inhibitor of the targetable and oncogenic MET/HGF pathway in lung cancer.• Determined a novel tumor suppressor gene in lung cancer after engineering of lentiviral vectors for the overexpression and knockdown of ETS2 in lung cancer cell lines.• In-depth analysis of ETS2 expression in public and institutional lung cancer datasets. • Conducted mechanistic molecular studies using lung cancer patient specimens and cell lines• Validated novel lung airway biomarkers predicting high risk of lung cancer in healthy smokers• Collaborated with stakeholders and supervised personals in the lung cancer prevention field• The research work was highlighted in the July 1st 2013 issue of Clinical Cancer Research, and considered as a breaking advance in their Highlights from Recent Cancer Literature• Presented findings in 2011, 2012 and 2013 at American Association for Cancer Research

Doctor Of Philosophy (Phd), Molecular Cellular And Developmental Biology

Master Of Science (Ms), Biology, General

Bachelor Of Science (Bs), Biology, General